PRRX1 and nonpapillary renal cell carcinoma: Furthermore, high expression of SOX2, PRRX1, or OCT2 correlates with poor patient outcome and worse survival rate, and therefore these three genes could be therapeutic targets for SETD2‐mutant ccRCC patients.